Roche’s Enspryng cuts relapse risk by 68% in rare neuroinflammatory disease

The era of off-label guesswork for patients living with the rare autoimmune disorder MOGAD may soon be over, as a phase 3 victory for Roche’s Enspryng suggests a first-of-its-kind FDA approval may not be far away.